Vaxxinity Inc. Class A Common Stock

Vaxxinity Inc. a biotechnology company focuses on developing product candidates for human use in the fields of neurology cardiovascular diseases and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301 an anti-tau product candidate for various neurodegenerative conditions including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus which is in phase 3 clinical trial. Vaxxinity Inc. was founded in 2014 and is headquartered in Merritt Island Florida.